Company intelligence / Profile preview
Fapon Biopharma
Dongguan, Guangdong, Chinaen.faponbiopharma.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Fapon Biopharma has a differentiated pipeline of biologics targeting cancers and autoimmune diseases. Lead assets include fusion proteins and antibody-based therapeutics in preclinical and early clinical stages. Notable programs are in Phase 1 for advanced solid tumors and pancreatic cancer. The company leverages multiple proprietary platforms to generate novel drug candidates.
- Therapeutic areas
- Oncology
- Modalities
- Fusion proteinsMonoclonal antibodiesBispecific antibodiesDegrader-antibody conjugates
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
Beyond the preview
Go deeper on Fapon Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fapon Biopharma.